Biotech | March 01, 2022
South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
The joint initiative is called J-ARC Healthcare Solutions
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Subscribe To Our Newsletter & Stay Updated
